A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Lintuzumab, Antigens, CD33, Antibodies, Monoclonal, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Hematologic Diseases, Myeloproliferative Disorders, Leukemia
Eligibility Criteria
Inclusion Criteria: Patients must have a diagnosis of MDS or AML. Patients must have an ECOG performance status ≤ 2 and a life expectancy > 3 months. Exclusion Criteria: Patients who have received prior therapy with gemtuzumab ozogamicin (Mylotarg®) or other anti-CD33 monoclonal antibody treatment. Patients with a prior allogeneic transplant. Patients with known leptomeningeal or CNS involvement of leukemia. Patients with onset of CNS symptoms within the past 12 months will also be excluded. Patients receiving chemotherapy within the last four weeks.
Sites / Locations
- Rocky Mountain Cancer Center
- Cancer Care Specialists of Central Illinois
- Indiana Oncology-Hematology Consultants
- University of Massachusetts Medical Center
- St. Vincent's Comprehensive Cancer Center
- Memorial Sloan Kettering Cancer Center
- Weill Medical College of Cornell University
- Cancer Center of the Carolinas
- Scott & White Memorial Hospital
Arms of the Study
Arm 1
Experimental
1